Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune (ALT)
:ALT
ALT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.28 - $14.84
Previous CloseN/A
Volume1.55M
Average Volume (3M)2.10M
Market Cap
$471.56M
Enterprise Value$298.81M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Feb 27, 2025EPS Estimate
-0.33Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding71,124,626
10 Day Avg. Volume2,158,416
30 Day Avg. Volume2,104,876
Standard Deviation0.56
R-Squared0.00025
Alpha0.11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9068.39
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.86K
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$20.60Price Target Upside220.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ApprovalsThe FDA agreed on the innovative Phase III design evaluating pemvidutide in different obesity subpopulations, which highlights its potential in treating obesity.
Market PotentialPemvidutide may generate peak annual revenues of nearly $1 billion in obesity alone, reflecting strong market potential.
Bears Say
Regulatory ChallengesNot risk-adjusted, pemvidutide may generate peak annual revenues of nearly $1B in obesity alone.
---
Ownership Overview
0.96% Insiders
11.73% Mutual Funds
8.70% Other Institutional Investors
64.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $5.28 and its highest was $14.84 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $471.56M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Feb 27, 2025 which is in 4 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on Nov 12, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.037.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.33.
How many shares outstanding does Altimmune have?
Altimmune has 71,124,626 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went up 29.116%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
---
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.60 (220.37% Upside)
$20.60 (220.37% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.77%
12-Months-Change
Fundamentals
Return on Equity
-72.96%
Trailing 12-Months
Asset Growth
-11.23%
Trailing 12-Months
Company Description
Altimmune
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
ALT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of pemvidutide, including successful trial enrollments and FDA alignment on Phase III plans. However, financial challenges such as increased net loss and decreased cash reserves were noted. Overall, the sentiment leans positive due to the strategic advancements and strong cash position to support future developments.Read More>---
ALT Stock 12 Month Forecast
Average Price Target
$20.60
▲(220.37% Upside)
Technical Analysis
Best Analysts Covering ALT
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+1.29%
reiterated a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.29% per trade.
---